Accession Number:



Prediction of Metastasis Using Second Harmonic Generation

Descriptive Note:

Technical Report,01 May 2015,30 Apr 2016

Corporate Author:

University of Rochester Rochester United States

Personal Author(s):

Report Date:


Pagination or Media Count:



A breast cancer patient with estrogen receptor positive ER invasive ductal carcinoma IDC typically has the tumor removed, possibly with nearby lymph nodes, and hormonal therapy is begun. Then a significant decision is made should the patient receive adjuvant chemotherapy to attack cells that have escaped the tumor In IDC ER patients whose cancer has spread to the lymph nodes the choice is clear and virtually all are treated systemically. However, in the majority of IDC ER cases the cancer has not yet spread N0, and the choice is unclear. Current data suggests that about half of patients that are systemically treated would not have metastasized, did not need to suffer the toxic effects of systemic therapy, and were overtreated. Hence there is a pressing need to predict who will, and will not, metastasize, to minimize overtreatment. We hypothesize that SHG FB is a clinically useful predictor of metastatic outcome. In an existing TMA we will answer the following questions 1 Does FB predict metastatic outcome in IDC patients 2 Does FB predict metastatic outcome in ER IDC patients 3 Does FB predict metastatic outcome in ER IDC patients treated with hormonal, chemo, andor radiotherapy

Subject Categories:

Distribution Statement: